CTOs on the Move

Family Care Center

www.fcsprings.com

 
Family Care Center provides counseling, medication management, and TMS. We specialize in mental health care for the entire family. Call today to learn more.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.fcsprings.com
  • 1330, Quail Lake Loop
    Colorado Springs, CO USA 80906
  • Phone: 719.540.2146

Executives

Name Title Contact Details

Similar Companies

Specialty Therapeutic Care

Specialty Therapeutic Care is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clearside Biomedical

Clearside Biomedical, Inc. is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye.

American Board of Pain Medicine

American Board of Pain Medicine is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fulcrum Pharma Developments

Fulcrum Pharma Developments Inc. is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.